ArriVent reports publication of firmonertinib in EGFR PACC-mutant NSCLC.
ArriVent BioPharma announced positive preclinical and clinical results from the FURTHER Phase 1b trial of firmonertinib for advanced EGFR PACC-mutant NSCLC. The company believes these results lay a strong foundation for its ongoing global Phase 3 ALPACCA trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed